Aspirin might reduce the incidence of pancreatic cancer: A meta-analysis of observational studies

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Zhang, Yan Peng ^a   Wan, You Dong ^a   Sun, Yu Ling ^a   Li, Jian ^a   Zhu, Rong Tao ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

CASE CONTROL STUDY; HUMAN; MEDLINE; META ANALYSIS; MORTALITY; PANCREAS TUMOR; PATHOLOGY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CASE-CONTROL STUDIES; HUMANS; PANCREATIC NEOPLASMS; PUBMED;

EID: 84944871588     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep15460     Document Type: Article

References (48)

1. Jemal, A., Siegel, R., Xu, J. & Ward, E. Cancer statistics, 2010. CA Cancer J Clin 60, 277 (2010).
2. Neoptolemos, J. P. et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350, 1200 (2004).
3. de Groot, D. J., de Vries, E. G., Groen, H. J. & de Jong, S., Non-steroidal anti-inflammatory drugs to potentiate chemotherapy effects: from lab to clinic. Crit Rev Oncol Hematol 61, 52 (2007).
4. Flower, R. J. The development of COX2 inhibitors. Nat Rev Drug Discov 2, 179 (2003).
5. Ali, S. et al. Concurrent inhibition of NF-kappaB, cyclooxygenase-2, and epidermal growth factor receptor leads to greater antitumor activity in pancreatic cancer. J Cell Biochem 110, 171 (2010).
6. Tucker, O. N. et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 59, 987 (1999).
7. Cole, B. F. et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst 101, 256 (2009).
8. Khuder, S. A. & Mutgi, A. B. Breast cancer and NSAID use: a meta-analysis. Br J Cancer 84, 1188 (2001).
9. Abnet, C. C. et al. Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis. Br J Cancer 100, 551 (2009).
10. Gonzalez-Perez, A., Garcia, R. L. & Lopez-Ridaura, R. Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis. Bmc Cancer 3, 28 (2003).
11. Xu, J. et al. Meta-analysis on the association between nonsteroidal anti-inflammatory drug use and lung cancer risk. Clin Lung Cancer 13, 44 (2012).
12. Liu, Y. et al. Effect of aspirin and other non-steroidal anti-inflammatory drugs on prostate cancer incidence and mortality: a systematic review and meta-analysis. Bmc Med 12, 55 (2014).
13. Friis, S. et al. A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer 88, 684 (2003).
14. Schernhammer, E. S. et al. A prospective study of aspirin use and the risk of pancreatic cancer in women. J Natl Cancer Inst 96, 22 (2004).
15. Schreinemachers, D. M. & Everson, R. B. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5, 138 (1994).
16. Ratnasinghe, L. D. et al. Aspirin use and mortality from cancer in a prospective cohort study. Anticancer Res 24, 3177 (2004).
17. Jacobs, E. J. et al. Aspirin use and pancreatic cancer mortality in a large United States cohort. J Natl Cancer Inst 96, 524 (2004).
18. Bonifazi, M. et al. Aspirin use and pancreatic cancer risk. Eur J Cancer Prev 19, 352 (2010).
19. Tan, X. L. et al. Aspirin, nonsteroidal anti-inflammatory drugs, acetaminophen, and pancreatic cancer risk: a clinic-based casecontrol study. Cancer Prev Res (Phila) 4, 1835 (2011).
20. Pugh, T. F. G. et al. Aspirin, NSAIDS, Calcium-channel blockers and statins in the aetiology of pancreatic cancer: preliminary results from a case-control study in two centres in the UK. Gut 60 A81 (2011).
21. Anderson, K. E., Johnson, T. W., Lazovich, D. & Folsom, A. R. Association between nonsteroidal anti-inflammatory drug use and the incidence of pancreatic cancer. J Natl Cancer Inst 94, 1168 (2002).
22. Streicher, S. A., Yu, H., Lu, L., Kidd, M. S. & Risch, H. A. Case-control study of aspirin use and risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev 23, 1254 (2014).
23. Jacobs, E. J., Newton, C. C., Gapstur, S. M. & Thun, M. J. Daily aspirin use and cancer mortality in a large US cohort. J Natl Cancer Inst 104, 1208 (2012).
24. Langman, M. J., Cheng, K. K., Gilman, E. A. & Lancashire, R. J. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 320, 1642 (2000).
25. Bradley, M. C., Hughes, C. M., Cantwell, M. M., Napolitano, G. & Murray, L. J., Non-steroidal anti-inflammatory drugs and pancreatic cancer risk: a nested case-control study. Br J Cancer 102, 1415 (2010).
26. Coogan, P. F. et al. Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel. Cancer Epidemiol Biomarkers Prev 9, 119 (2000).
27. Menezes, R. J., Huber, K. R., Mahoney, M. C. & Moysich, K. B. Regular use of aspirin and pancreatic cancer risk. Bmc Public Health 2, 18 (2002).
28. Sorensen, H. T. et al. Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer 88, 1687 (2003).
29. Larsson, S. C., Giovannucci, E., Bergkvist, L. & Wolk, A. Aspirin and nonsteroidal anti-inflammatory drug use and risk of pancreatic cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 15, 2561 (2006).
30. Capurso, G. et al. Meta-analysis: the use of non-steroidal anti-inflammatory drugs and pancreatic cancer risk for different exposure categories. Aliment Pharmacol Ther 26, 1089 (2007).
31. Cui, X. J. et al. High-dose aspirin consumption contributes to decreased risk for pancreatic cancer in a systematic review and meta-analysis. Pancreas 43, 135 (2014).
32. Hannan, E. L. Randomized clinical trials and observational studies: guidelines for assessing respective strengths and limitations. JACC Cardiovasc Interv 1, 211 (2008).
33. Rothwell, P. M. et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377, 31 (2011).
34. Cook, N. R. et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 294, 47 (2005).
35. Dovizio, M., Bruno, A., Tacconelli, S. & Patrignani, P. Mode of action of aspirin as a chemopreventive agent. Recent Results Cancer Res 191, 39 (2013).
36. Gobbi, P. G. et al. The prognostic role of time to diagnosis and presenting symptoms in patients with pancreatic cancer. Cancer Epidemiol 37, 186 (2013).
37. Wolff, T., Miller, T. & Ko, S., Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 150, 405 (2009).
38. Newby, L. K. et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation 113, 203 (2006).
39. Yachida, S. et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467, 1114 (2010).
40. Patrono, C., Garcia, R. L., Landolfi, R. & Baigent, C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 353, 2373 (2005).
41. Permuth-Wey, J. & Egan, K. M. Family history is a significant risk factor for pancreatic cancer: results from a systematic review and meta-analysis. Fam Cancer 8, 109 (2009).
42. Moher, D., Liberati, A., Tetzlaff, J. & Altman, D. G., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Plos Med 6, e1000097 (2009).
43. Stang, A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in metaanalyses. Eur J Epidemiol 25, 603 (2010).
44. Greenland, S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 9, 1 (1987).
45. Higgins, J. P. & Thompson, S. G. Quantifying heterogeneity in a meta-analysis. Stat Med 21, 1539 (2002).
46. DerSimonian, R. & Laird, N. Meta-analysis in clinical trials. Control Clin Trials 7, 177 (1986).
47. Egger, M., Davey, S. G., Schneider, M. & Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ 315, 629 (1997).
48. Sterne, J. A. et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 343, d4002 (2011).